Skip to main content
. 2017 Jun 21;42(13):2567–2574. doi: 10.1038/npp.2017.106

Table 1. Demographic and Clinical Characteristics of Patients with Major Depressive Disorder Receiving an Antidepressant Plus Adjunctive Riluzole or Placebo.

Characteristic Placebo/Placebo (N=40) Placebo/Riluzole (N=39) Riluzole/Riluzole (N=25)
Study group (n (%))
 A 16 (40.0) 14 (35.9) 9 (36.0)
 B 24 (60.0) 25 (64.1 16 (64.0)
       
Female (n (%)) 21 (52.5) 24 (61.5) 9 (36.0)
Race/Ethnicity
 Caucasian 32 (84.2) 34 (89.5) 16 (66.7)
 African American 3 (7.9) 4 (10.5) 4 (16.7)
 Hispanic 6 (15.4) 5 (13.5) 2 (8.3)
 Other 3 (7.9) 0 4 (16.7)
       
Education completed (n (%)
 Grade 6–12 or graduated high school 5 (12.5) 6 (15.8) 6 (24.0)
 Some college 15 (38.4) 13 (34.2) 6 (24.0)
 Graduated 4 year college 12 (30.8) 12 (31.6) 7 (28.0)
 Graduate/professional degree 7 (18.0) 7 (18.4) 6 (24.0)
       
Current Marital Status (n (%))
 Single, never married 18 (51.4) 13 (39.4) 7 (31.8)
 Married, civil union, cohabitating 9 (25.7) 15 (45.4) 5 (22.7)
 Separated, divorced, widowed 8 (22.9) 5 (15.2) 10 (45.5)
       
Current employment status (n (%))
 Full-time 9 (23.1) 8 (21.1) 8 (32.0)
 Part-time 11 (28.2) 8 (21.1) 4 (16.0)
 Not employed 19 (48.7) 22 (57.8) 13 (52.0)
       
History of suicidal behavior (n (%)) 5 (12.5) 6 (15.8) 7 (28.0)
Comorbid anxiety disorder (n (%)) 12 (30.0) 7 (18.0) 5 (20.0)
Age (years) 46.3±12.7 47.3±12.1 44.5±12.2
Montgomery-Asberg depression rating scale (mean±SD) 28.7±5.9 30.0±6.0 29.8±5.9
Clinical global impressions scale, severity subscale 4.4±0.6 4.4±0.7 4.4±0.8
Inventory of depressive symptomatology-self report 42.1±13.5 42.2±12.0 43.6±11.0
Cognitive and physical functioning questionnaire 26.7±6.7 27.9±5.4 28.4±5.7